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Knowledge of the within-subject variability of 18F-FDG PET/MRI
measurements is necessary for proper interpretation of quantitative
PET or MRI metrics in the context of therapeutic efficacy assess-
ments with integrated PET/MRI scanners. The goal of this study was
to determine the test–retest repeatability of these metrics on PET/
MRI, with comparison to similar metrics acquired by PET/CT.Methods:
This prospective study enrolled subjects with pathology-proven pelvic
malignancies. Baseline imaging consisted of PET/CT immediately fol-
lowed by PET/MRI, using a single 370-MBq 18F-FDG dose. Repeat
imaging was performed within 7 d using an identical imaging protocol,
with no oncologic therapy between sessions. PET imaging on both
scanners consisted of a list-mode acquisition at a single pelvic station.
The MRI consisted of 2-point Dixon imaging for attenuation correction,
standard sequences for anatomic correlation, and diffusion-weighted
imaging. PET data were statically reconstructed using various frame
durations and minimizing uptake time differences between ses-
sions. SUV metrics were extracted for both PET/CT and PET/MRI
in each imaging session. Apparent diffusion coefficient (ADC) metrics
were extracted for both PET/MRI sessions. Results: The study cohort
consisted of 14 subjects (13 female, 1 male) with various pelvic cancers
(11 cervical, 2 rectal, 1 endometrial). For SUVmax, the within-subject co-
efficient of variation (wCV) appeared higher for PET/CT (8.5%–12.8%)
than PET/MRI (6.6%–8.7%) across all PET reconstructions, though with
no significant repeatability differences (all P values $ 0.08) between
modalities. For lean body mass-adjusted SUVpeak, the wCVs appeared
similar for PET/CT (9.9%–11.5%) and PET/MRI (9.2%–11.3%) across all
PET reconstructions, again with no significant repeatability differences
(all P values $ 0.14) between modalities. For PET/MRI, the wCV for
ADCmedian of 3.5% appeared lower than the wCVs for SUVmax
(6.6%–8.7%) and SULpeak (9.2%–11.3%), though without significant
repeatability differences (all P values $ 0.23). Conclusion: For solid
tumors of the pelvis, the repeatability of the evaluated SUV and ADC
metrics on 18F-FDG PET/MRI is both acceptably high and similar to
previously published values for 18F-FDG PET/CT and MRI, supporting
the use of 18F-FDG PET/MRI for quantitative oncologic treatment
response assessments.
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Semiquantitative assessments of 18F-FDG uptake on PET/CT
with metrics such as the SUV are valuable tools for oncologic re-
sponse assessment (1). Knowledge of measurement variability is
essential to the interpretation of longitudinal changes in such met-
rics. Prior PET/CT studies have shown that serial measurements
of 18F-FDG uptake are highly repeatable (2). However, 18F-FDG
PET/CT has important limitations. For example, the low soft-tissue
contrast of CT impedes primary tumor staging, whereas high back-
ground 18F-FDG uptake in some organs may reduce the conspicuity
of metastases. Consequently, many patients also undergo MRI to
improve staging accuracy.
Simultaneous PET/MRI systems can provide whole-body staging
and treatment response assessment in a single examination (3). These
hybrid systems have necessitated the development of MRI-based
methods for attenuation correction (4). MRI-based attenuation cor-
rection maps are often affected by artifacts that can vary between
imaging sessions, potentially reducing the repeatability of PET quan-
titation (5). In contrast, the CT-based attenuation correction approach
used by PET/CTentails the direct measurement of photon attenuation
by tissues, a method that is uncommonly affected by serious artifacts.
The repeatability of PET metrics for PET/MRI relative to PET/CT is
largely unknown.
Furthermore, PET/MRI permits the assessment of cellular density
with diffusion-weighted imaging (DWI). In studies of MRI alone,
quantitative metrics such as the apparent diffusion coefficient (ADC)
have been used to track response to treatment or predict clinical
outcomes (6,7). The repeatability of ADCmetrics for integrated PET/
MRI systems is unknown and might be different from MRI-only
systems. For example, prior studies have suggested that the addi-
tion of PET hardware to MRI systems can worsen DWI artifacts
related to eddy currents, creating the potential for greater variability
in ADC values between imaging sessions (8).
Thus, the primary aim of this study was to determine the test–
retest repeatability of several commonly used PET/MRI-based
quantitative imaging metrics in patients with solid malignancies
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of the pelvis. The specific metrics of interest were SUVmax, peak
lean body mass–adjusted SUV (SULpeak), and ADCmedian. The
repeatability of other PET and MRI metrics of potential clinical
interest was also assessed in an exploratory analysis, the results of
which are presented separately. A secondary aim was to evaluate
the impact of various PET reconstruction techniques and frame
durations on the repeatability of the above-described PET metrics.
MATERIALS AND METHODS
Subjects
This prospective study (ClinicalTrials.gov identifier NCT02717572)
was approved by our Institutional Review Board. Inclusion and exclusion
criteria are listed in Table 1. From June 2016 through May 2017, 17
subjects were enrolled. All subjects provided written informed con-
sent. Two subjects were excluded because of failure to complete the
second imaging session, and one was excluded because of lack of 18F-
FDG uptake, which was presumably due to prior therapy.
Study Protocol
Subjects underwent 2 imaging sessions separated by 1–7 d without
any intervening oncologic treatments (Fig. 1). Immediately before the
PET/MRI, subjects received 1 mg of intravenous glucagon to minimize
artifacts related to bowel motility.
PET/CT
All subjects were imaged on a Biograph 40 TruePoint/TrueView
PET/CT scanner (Siemens AG). List-mode PET data were collected
for 15 min for a single pelvic station (tumor centered craniocaudally
within a 21.6-cm z-axis field of view), starting approximately 60 min
after the intravenous injection of a 370-MBq 18F-FDG dose. A low-dose
CT scan was acquired for anatomic correlation and attenuation as fol-
lows: 50 mAs (effective; CareDose tube current modulation), 120 kVp,
0.8 pitch, 0.5-s rotation time.
PET/MRI
Immediately after PET/CT, all subjects were imaged on a Biograph
mMR PET/MRI scanner, software version VA40 (Siemens AG). List-
mode PET data were collected for 30 min (longer than for PET/CT
because of the duration of the MRI component) for a single pelvic
station (tumor centered craniocaudally within a 25.6-cm z-axis field of
view). To minimize subject exclusion due to artifacts, DWI was per-
formed twice during each session using the acquisition parameters in
Supplemental Table 1 (supplemental materials are available at http://
jnm.snmjournals.org). ADC maps were generated by the VA40 console
software.
PET Reconstructions
For each session, PET reconstructions derived from 1, 3, and 5 min
of list-mode data were performed for both PET/CT and PET/MRI. For
each subject, variable intervals were skipped at the beginning of each
list-mode acquisition to achieve identical effective uptake times for
PET/CT between sessions 1 and 2 and for PET/MRI between sessions 1
and 2 (Fig. 1). The reconstruction intervals were also selected to min-
imize uptake time differences between PET/CTand PET/MRI. For each
frame duration, static images were generated using an ordered-subset
expectation maximization reconstruction (OSEM) and an OSEM with
point-spread function reconstruction (PSF), the latter of which was used
to improve spatial resolution. Image reconstruction parameters are
shown in Supplemental Table 2.
Image Analysis
MIM version 6.7 (MIM Software) was used for image analysis. For
each PET session, the lesion of interest was manually delineated on
the basis of the perceived boundary between tumor and background,
thereby generating a whole-tumor contour that was propagated to all
6 reconstructions (1 min, 3 min, 5 min; OSEM and PSF).
For each whole-tumor contour, multiple PET metrics were extracted.
The term peak was defined as the highest mean value achievable for a
1-cm3 sphere placed within the lesion contour. Notably, MIM software
uses the James formula for calculating the lean body mass values
needed for SUL computation. For the exploratory analysis, metrics were
also extracted from a 40% isocontour, which contains all voxels with
an SUV at least 40% of the SUVmax in the whole-tumor contour, to
determine the effects of semiautomated lesion segmentation on repeat-
ability. The 40% isocontour was selected because of its correlation
with metabolic tumor volume in prior PET/MRI studies of cervical
cancer (9).
For each DWI acquisition, the lesion of interest was manually
delineated on the corresponding ADC map, based on the perceived
boundary between tumor and background diffusion properties. For each
ADC contour, multiple metrics were extracted. For some acquisitions,
the images were unusable because of severe artifacts related to
incomplete fat suppression. For 1 subject, all 4 DWI acquisitions were
inadequate. For another subject, both DWI acquisitions in the second
imaging session were inadequate. Consequently, only 12 subjects could
be included in the ADC repeatability analysis.
Statistical Analysis
Subject characteristics were summarized descriptively using means
6 SD for continuous metrics. The Wilcoxon signed-rank test was used
to assess for differences in metric values between sessions 1 and 2.
The repeatability analysis was performed according to the methods
of Bland and Altman (10). Percentage differences (%D) in measure-
ments between sessions were used instead of absolute differences. For
each metric, the SD of the distribution of %D values from all subjects
was calculated. The wCV was defined as wCV5SD=
ffiffiffi
2
p
. The repeat-
ability coefficient was defined as 1:96  SD. The %D between measure-
ments is expected fall within 1 repeatability coefficient of the mean %D
(in either direction) in approximately 95% of cases.
TABLE 1
Inclusion and Exclusion Criteria
Parameter Criterion
Inclusion Histologically confirmed malignant
solid tumor of pelvis (primary or
metastatic; newly diagnosed
or recurrent)
Maximum tumor diameter $ 2.0 cm
Age $ 18 y
Ability to provide informed consent
Ability to tolerate 60 min of
supine imaging
Exclusion Oncologic therapy within 30 d
before enrollment (to minimize
treatment-related changes in
tumor behavior between sessions)
Uncontrolled intercurrent illness
(e.g., active infections)
Insulin-dependent diabetes mellitus
Prostheses incompatible with 3-T
magnetic fields
Pregnancy or nursing
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The normality of the %D distributions was assessed via visual in-
spection of Q-Q plots. Natural log transformation was attempted for
metrics with nonnormal distributions, because repeatability statistics
derived from natural log-transformed data are directly interpretable as
nontransformed relative difference repeatability statistics (11). These
transformations did not successfully normalize the distributions of the
nonnormal metrics (data not shown). However, as stated by Bland and
Altman, deviations from normality are generally not problematic in the
setting of repeatability analyses, in contrast to other areas of statis-
tics (11). Consequently, repeatability coefficients were generated from
the nonnormal metrics without transformation, as denoted in the appro-
priate tables.
The Wilcoxon signed-rank test (paired data) or Mann–Whitney U
test (unpaired data) was used to evaluate for significant differences in
repeatability. If there are no systematic differences in measurements
between sessions, the mean %D will be approximately 0% even when
there are large %D values, provided that those %D values are ran-
domly distributed in the positive and negative directions. In contrast,
the mean j%Dj (i.e., the mean of the absolute values of the %D values)
will be 0% only with perfect repeatability, with larger values indicat-
ing greater magnitudes of %D between sessions (irrespective of
whether these changes are increases or decreases). On the basis of
clinical interest and relevance, a limited subset of metrics was selected
for pairwise comparison via the mean j%Dj, as the total number of
possible pairs was prohibitively large.
Because of the large number of statistical tests, the methods of
Benjamini and Hochberg were used to achieve a false-discovery rate
of 5% (12). This correction was performed separately for the primary
and exploratory aims, with statistical significance defined as P # 0.01
and P # 0.007, respectively. All statistical analysis was performed in
R version 3.4.
RESULTS
Subject Characteristics
The final study cohort consisted of 14 subjects with pelvic
tumors, with characteristics summarized in Table 2. All subjects
but one were imaged at the time of initial cancer diagnosis. This pre-
viously treated subject had a pelvic recurrence of rectal adenocarcinoma.
Mean serum glucose levels for sessions 1
and 2 were 96 and 97 mg/dL, respectively.
PET Metrics on PET/CT Versus PET/
MRI
There were systematic differences in
18F-FDG uptake times for PET/CT versus
PET/MRI (Fig. 1). The mean endpoint for
the PET/CT reconstructions was 75.1 min
(range, 75–77 min) after injection. The mean
start-point for the PET/MRI reconstruc-
tions was 95.8 min (range, 88–105 min)
after injection.
Supplemental Table 3 shows mean val-
ues of SUVmax and SULpeak on PET/CT
versus PET/MRI for OSEM and PSF re-
constructions (Supplemental Table 4 shows
exploratory PET metrics). On average, the
values of all PET metrics except metabolic
tumor volume were numerically lower on
PET/MRI than PET/CT, regardless of
frame duration. These differences were
statistically significant for 7 of 12 metrics
(58.3%; 5 from OSEM, 2 from PSF) in the
primary analysis and 12 of 72 metrics (16.7%; 11 from OSEM,
2 from PSF) in the exploratory analysis.
ADC Metrics for PET/MRI Session 1 Versus Session 2
Supplemental Table 5 shows the mean values of ADCmedian
(Supplemental Table 6 shows exploratory ADC metrics) on
FIGURE 1. Schematic of study imaging protocol. All subjects received 370 MBq of 18F-FDG at
0 min. PET/CT imaging began at 60 min, lasting for 15 min. Immediately after PET/CT, PET/MRI
began, lasting for 30 min. DWI was performed at beginning (DWI 1) and at end (DWI 2) of PET/MRI
session. Occasionally, because of various subject-related factors, session 2 imaging began at a
different time from session 1 imaging (note horizontal offset in bars representing PET/CT sessions
1 and 2 and PET/MRI sessions 1 and 2). To control for these differences, static PET images were
reconstructed using overlapping intervals of 1, 3, and 5 min in PET data (brackets), thereby
achieving identical effective uptake times. To minimize differences in uptake times between PET/
MRI and PET/CT, these reconstruction intervals were selected from latest overlapping portion for
PET/CT and earliest overlapping portion for PET/MRI.
TABLE 2
Subject Characteristics
Characteristic Data
Age (y) 48.1 ± 10.5
Height (m) 1.7 ± 0.1
Weight (kg) 82.5 ± 21.0
Body mass index (kg/m2) 29.7 ± 6.4
Sex
Male 1 (7)
Female 13 (93)
Race/ethnicity
Caucasian (non-Hispanic) 12 (86)
Caucasian (Hispanic) 1 (7)
African-American 1 (7)
Histologic diagnosis
Cervical squamous cell carcinoma 11 (79)
Colorectal adenocarcinoma 2 (14)
Endometrial adenocarcinoma 1 (7)
Treatment status
Initial diagnosis 13 (93)
Recurrent disease 1 (7)
Qualitative data are expressed as numbers followed by percent-
ages in parentheses; continuous data are expressed as mean ± SD.
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PET/MRI for both imaging sessions. Mean values were nearly iden-
tical between sessions for all ADC metrics. Notably, there was no
significant difference in diffusional tumor volume between sessions
(P 5 0.64).
Repeatability of PET and ADC Metrics
Supplemental Table 7 shows repeatability results for SUVmax
and SULpeak on PET/CT and PET/MRI for the OSEM and PSF
reconstructions (Supplemental Table 8 shows exploratory PET
metrics). Relative differences between sessions, as reflected by
the mean %Δ (range, 29.8%, 6.0%), were small for all metrics.
For a given metric, within-subject coefficients of variation (wCVs)
were generally similar across different reconstruction intervals
(i.e., 1 min, 3 min, 5 min) and algorithms (i.e., OSEM, PSF). Re-
peatability results from the 3-min PSF reconstructions are shown in
the form of Bland–Altman plots for SUVmax (Fig. 2) and SULpeak
(Fig. 3). The PET image analysis for a subject with excellent SULpeak
repeatability is also shown (Fig. 4).
Supplemental Table 9 shows repeatability results for ADCmedian
on PET/MRI (Supplemental Table 10 shows exploratory ADC
metrics). Relative differences between sessions, as reflected by
the mean %Δ (range, 22.7%, 0.5%), were small for all metrics. In-
terestingly, ADC metric wCVs were generally lower than PET metric
wCVs. Repeatability results for ADCmedian are shown in the form
of a Bland–Altman plot (Fig. 5). The ADC map analysis for a subject
with excellent ADCmedian repeatability is also shown (Fig. 6).
Supplemental Table 11 shows the results of pairwise repeatability
comparisons of SUVmax, SULpeak, and ADCmedian (Supplemental
Table 12 shows pairwise repeatability comparisons of exploratory
PET and ADC metrics). Notably, for many of the comparisons of
PET/CT to PET/MRI, the mean j%Dj was numerically lower on
PET/MRI, though without statistical significance. There were also
no significant differences in mean j%Dj for the PET-versus-ADC
metric pairs evaluated.
DISCUSSION
We have demonstrated the repeatability of various quantitative
PET and MRI metrics on simultaneous PET/MRI. Our results
point to the robustness of PET/MRI for use in clinical trials with
quantitative endpoints, incorporation into treatment response assess-
ment algorithms, and (eventually) prediction of tumor biology and
clinical outcomes. Our focus on pelvic tumors reflects the expected
value of PET/MRI for such malignancies based on prior studies of
cervical (13–15) and rectal cancer (16). Furthermore, although
other studies have assessed the repeatability of ADC metrics on
MRI platforms, our study is the first (to our knowledge) to address
DWI repeatability on simultaneous PET/MRI. The repeatability of
DWI on PET/MRI is especially important to establish given the
potential clinical value of PET/MRI-based biomarkers incorporat-
ing both SUV and ADC data (17).
With respect to the magnitude of PET metrics, values were
generally lower on PET/MRI than PET/CT. These differences are
likely not related to the systematically longer uptake times for
PET/MRI, as delayed PET imaging generally results in higher
SUVs for malignant lesions (18), but may instead be due to PET
photon attenuation by the MRI body phased-array coils, which are
not captured by PET/MRI attenuation correction algorithms. Fur-
thermore, most cancers in our study arose in the cervix or rectum,
both of which are surrounded by bony structures. The Siemens
mMR, which uses a Dixon-based segmentation approach with 4
tissue classes (soft tissue, fat, lung, air) (4), may have undercor-
rected for the attenuation effects of cortical bone relative to PET/
CT, resulting in lower SUVs. Newer approaches using ultrashort
echo times have been successful in delineating cortical bone for
attenuation correction of PET data in PET/MRI studies (19). The
PSF reconstructions seemed to reduce quantitative differences be-
tween PET/MRI and PET/CT, suggesting that PSF might be best
for such scanner comparisons.
FIGURE 2. Bland–Altman plots for SUVmax. For SUVmax from PSF 3-min reconstructions on PET/CT (A) and PET/MRI (B), Bland–Altman plots are
shown. For each subject (ο), percentage change (%Δ) between measurements (y-axis) is plotted against mean of 2 measurements. Orange line (μ)
indicates mean %Δ across all subjects; dotted lines indicate 1 SD from mean %Δ; solid black lines indicate 1.96 SDs from mean %Δ, constituting
95% limits of repeatability (range of %Δ within which 95% of observations are expected to fall). Distance along y-axis between μ and either 1.96 SD
line is repeatability coefficient. Comparing plots in A and B (identical y-axis ranges), 95% limits of repeatability appear substantially narrower for PET/
MRI; correspondingly, repeatability coefficient and wCV were larger for PET/CT than PET/MRI. LOR5 95% limits of repeatability; RC5 repeatability
coefficient.
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With respect to the repeatability of PET metrics, our results are
consistent with published results for 18F-FDG PET/CT. To facilitate
comparisons, repeatability coefficients reported by other authors
were converted as needed into wCVs. For example, a metaanalysis
of 12 studies of various malignancies found a mean wCVof 11.0%
for SUVmax (20). In our study, SUVmax wCVs ranged from 8.5%
to 12.8% for PET/CT and 6.6% to 8.7% for PET/MRI, with similar
results for the other PET metrics. Two of the studies included in
the metaanalysis focused on pelvic malignancies (though neither
included PET/MRI), with an SUVmax wCVof 10.7% for colorectal
cancer (21) and 6.3% for ovarian cancer (22).
To our knowledge, there are only 2 other studies that have
assessed the repeatability of PET metrics on PET/MRI. One study
of head/neck cancers found SUVmax wCVs of 7.6% and 6.4% for
PET/CT and PET/MRI, respectively, with similar wCVs for SUVpeak
and SUVmean (23). In contrast, our PET metric wCVs were generally
higher, potentially reflecting differences in biology between head/
neck and pelvic cancers or differences in the surrounding anatomy,
as various physiologic processes specific to the pelvis (e.g., blad-
der filling, bowel peristalsis) might introduce greater variability
between imaging sessions. As in our study, the authors found no
statistically significant differences in repeatability between PET/
CT and PET/MRI. The second repeatability study enrolled 33
subjects with various malignancies, including 7 colorectal cancers
but no cervical cancers (24). In a single session (i.e., 1 18F-FDG
dose), subjects underwent either 1 PET/CT exam followed by 2
PET/MRI exams or 2 PET/MRI exams followed by 1 PET/CT
exam. Despite study design differences, their PET metric wCVs
for PET/MRI were generally in the 7.9%–11.2% range, on par
with ours.
For the ADC metrics, our results compare favorably with those
published in a recent metaanalysis of ADC repeatability for
extracranial soft-tissue tumors (25). This study found a mean wCV
across 12 studies of 4.1% for ADCmedian, slightly higher than our
ADCmedian wCVof 3.5%. We observed similarly low wCVs for the
exploratory ADC metrics, suggesting that these metrics are also
quantitatively robust. Notably, the ADCtrough, unlike the other ADC
metrics evaluated, can be determined quickly and in a relatively
user-independent fashion, suggesting that it may be preferable to
FIGURE 3. Bland–Altman plots for SULpeak. For SULpeak from PSF 3 min reconstructions on PET/CT (A) and PET/MRI (B), Bland–Altman plots are
shown. For each subject (ο), percentage change (%Δ) between measurements (y-axis) is plotted against mean of 2 measurements. Orange line (μ)
indicates mean %Δ across all subjects; dotted lines indicate 1 SD from mean %Δ; solid black lines indicate 1.96 SDs from mean %Δ, constituting
95% limits of repeatability (range of %Δ within which 95% of observations are expected to fall). Distance along y-axis between μ and either 1.96 SD
line is repeatability coefficient. Comparing plots in A and B (identical y-axis ranges), 95% limits of repeatability appear slightly narrower for PET/MRI;
correspondingly, repeatability coefficient and wCV were slightly larger for PET/CT than PET/MRI. LOR 5 95% limits of repeatability; RC 5 re-
peatability coefficient.
FIGURE 4. SULpeak repeatability from PET image analysis. A 65-y-old
woman with biopsy-proven squamous cell carcinoma of cervix was im-
aged with 24 h between session 1 (A) and session 2 (B). Transaxial PET
images with manual whole-tumor contours (pink), T2-weighted MR im-
ages, and fused PET/MR images are shown from top to bottom for each
imaging session. Note intersession contour similarities. SULpeak (small
pink sphere) was located in same tumor region for both sessions, with
similar values.
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the other ADC measures from a clinical workflow perspective.
DWI is appealing for treatment response assessment, as ADC
metrics (unlike PET metrics) do not require any radiation exposure,
preexamination fasting, or control for variation in uptake times be-
tween imaging sessions. However, unlike PET, DWI can be im-
peded by susceptibility artifacts; by chemical shift artifacts from
fat suppression failure; or by intralesional fibrosis, which can de-
velop in the tumor interstitium during treatment, resulting in low
signal on ADC maps that can mimic or obscure residual or re-
current disease (26).
Our study had some limitations. First, the comparison of
repeatability on PET/CT versus PET/MRI is confounded by the
systematically longer uptake times for PET/MRI than for PET/CT.
Although the scan order could have been randomized on a per-
subject basis, this approach was not adopted because of concerns
about the potential for wide ranges of uptake times within each
scan type. Next, the applicability of our results to PET/MRI for
other solid tumors is uncertain, as most tumors in our study were
cervical cancers. It is conceivable that distinct tumor types might
exhibit differences in the intrinsic variability of PET or ADC
metrics. Likewise, the impact of respiratory and cardiac motion on
repeatability was not tested in this study, as we focused on the
pelvis only. Additionally, given that study subjects were not on any
oncologic therapies between imaging sessions, it is possible (though
unlikely) that there were substantial interval changes in tumor
metabolism or cellularity related to true tumor growth. The number
of subjects in our study was relatively small, reducing statistical
power for the detection of true (though likely small) differences in
repeatability between metrics. Finally, the degree to which our
results, which were derived from a single model of integrated PET/
MRI scanner, are generalizable to other PET/MRI scanner models is
unclear, though there is no reason to suspect substantial differences. CONCLUSION
We have demonstrated that the test–retest measurement repeat-
ability of various PET metrics on 18F-FDG PET/MRI is both
acceptably high and similar to values for 18F-FDG PET/CT, across
all PET reconstructions. These findings support the use of quan-
titative 18F-FDG PET/MRI within the framework of treatment re-
sponse assessment for cervical cancer and other solid tumors of
the pelvis.
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